Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from ...

This was the stock's second consecutive day of losses.

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

RFK Jr.'s upcoming MAHA report will address vaccines, ultra-processed foods, and children's health. Read more here.

In addition to Cantor Fitzgerald, Pfizer also received a Hold from Citi’s Geoff Meacham in a report issued on May 14. However, yesterday, BMO Capital maintained a Buy rating on Pfizer (NYSE: PFE). PFE ...

In an article published in The New England Journal of Medicine titled “An Evidence-Based Approach to Covid-19 Vaccination” by ...

The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.